<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02934139</url>
  </required_header>
  <id_info>
    <org_study_id>N91115-1HS-08</org_study_id>
    <nct_id>NCT02934139</nct_id>
  </id_info>
  <brief_title>MAD Study Evaluating the Safety, Tolerability, and Pharmacokinetics of Cavosonstat (N91115) in Healthy Subjects (SNO-9)</brief_title>
  <acronym>(SNO-9)</acronym>
  <official_title>A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of N91115 in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nivalis Therapeutics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Nivalis Therapeutics, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The present study is designed to assess the safety and tolerability of escalating, multiple&#xD;
      ascending doses of Cavosonstat (N91115) in healthy subjects.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study will assess the safety and tolerability of escalating, multiple ascending doses of&#xD;
      Cavosonstat (N91115) in healthy subjects.&#xD;
&#xD;
      Approximately 5 ascending cohorts are planned with approximately 8 subjects per cohort (6&#xD;
      active, 2 placebo). Each subject will undergo screening (Day -28 to Day -2) and, if eligible,&#xD;
      return to the unit on Day -1 when eligibility will be reconfirmed.&#xD;
&#xD;
      Eligible subjects will be randomized in a 3:1 ratio to receive investigational medicinal&#xD;
      product (IMP) N91115 (daily [QD] or every 12 hours [Q12H]) or matching placebo (QD or Q12H)&#xD;
      for 7 days and will be followed for safety while housed in the clinical research unit (CRU)&#xD;
      until discharge on Day 8. Pharmacokinetics will be followed from Study Day 1 through the&#xD;
      morning of Study Day 8. The subjects will be discharged from the CRU and complete the post&#xD;
      treatment withdrawal phase, including a follow-up phone call on Day 15.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2016</start_date>
  <completion_date type="Actual">January 2017</completion_date>
  <primary_completion_date type="Actual">December 2016</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]</measure>
    <time_frame>14 days</time_frame>
    <description>Safety assessments based on clinical evaluations, laboratory assessments, and adverse events</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic parameters of N91115 and metabolites (Amount of analyte excreted in the urine [Ae])</measure>
    <time_frame>7 days</time_frame>
    <description>Pharmacokinetic parameter of N91115 and metabolites will be measured in urine.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic parameters of N91115 and metabolites (% analyte excreted in the urine [Fe])</measure>
    <time_frame>7 days</time_frame>
    <description>Pharmacokinetic parameter of N91115 and metabolites will be measured in urine.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic parameters of N91115 and metabolites (area under the curve [AUC])</measure>
    <time_frame>7 days</time_frame>
    <description>Pharmacokinetic parameter of N91115 and metabolites will be measured in plasma.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic parameters of N91115 and metabolites (maximum concentration [Cmax])</measure>
    <time_frame>7 days</time_frame>
    <description>Pharmacokinetic parameter of N91115 and metabolites will be measured in plasma.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic parameters of N91115 and metabolites (clearance [CL])</measure>
    <time_frame>7 days</time_frame>
    <description>Pharmacokinetic parameter of N91115 and metabolites will be measured in urine and plasma.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic parameters of N91115 and metabolites (accumulation index [Racc])</measure>
    <time_frame>7 days</time_frame>
    <description>Pharmacokinetic parameter of N91115 and metabolites will be measured in plasma.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic parameters of N91115 and metabolites (Terminal elimination half-life [t1/2])</measure>
    <time_frame>7 days</time_frame>
    <description>Pharmacokinetic parameter of N91115 and metabolites will be measured in plasma.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic parameters of N91115 and metabolites (time of maximum concentration [Tmax])</measure>
    <time_frame>7 days</time_frame>
    <description>Pharmacokinetic parameter of N91115 and metabolites will be measured in plasma.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic parameters of N91115 and metabolites (metabolite to parent exposure ratio [M/P ratio])</measure>
    <time_frame>7 days</time_frame>
    <description>Pharmacokinetic parameter of N91115 and metabolites will be measured in plasma.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic parameters of N91115 and metabolites (terminal elimination rate constant [lambda z])</measure>
    <time_frame>7 days</time_frame>
    <description>Pharmacokinetic parameter of N91115 and metabolites will be measured in plasma.</description>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">32</enrollment>
  <condition>Cystic Fibrosis</condition>
  <arm_group>
    <arm_group_label>Cavosonstat (N91115) 400 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Every 12 hour oral dosing of N91115 for 7 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cavosonstat (N91115) 600 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Every 12 hour oral dosing of N91115 for 7 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cavosonstat (N91115) 1200 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Once daily oral dosing of N91115 for 7 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cavosonstat (N91115) 800 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Every 12 hour oral dosing of N91115 for 7 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Matched placebo. Oral dosing every 12 hour or once daily for 7 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cavosonstat</intervention_name>
    <description>CFTR modulator that stabilizes CFTR</description>
    <arm_group_label>Cavosonstat (N91115) 1200 mg</arm_group_label>
    <arm_group_label>Cavosonstat (N91115) 400 mg</arm_group_label>
    <arm_group_label>Cavosonstat (N91115) 600 mg</arm_group_label>
    <arm_group_label>Cavosonstat (N91115) 800 mg</arm_group_label>
    <other_name>N91115</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Matched placebo</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Written informed consent&#xD;
&#xD;
          2. Healthy, determined at the screening medical evaluation (including but not limited to&#xD;
             medical history, physical examination, and clinical laboratory evaluations)&#xD;
&#xD;
          3. Male or female, between 18 and 55 years of age, inclusive at screening&#xD;
&#xD;
          4. Caucasian (as reported by patient)&#xD;
&#xD;
          5. The following applies to female subjects:&#xD;
&#xD;
               1. Negative serum pregnancy test (for women of child-bearing potential) at screening&#xD;
                  and negative urine pregnancy at Day -1&#xD;
&#xD;
               2. Willing to use at least 1 highly effective method of birth control (excluding&#xD;
                  hormonal contraceptives) after signing consent, including abstinence which must&#xD;
                  be in use from the time of consent through the 30 days after completing the&#xD;
                  double-blind study drug&#xD;
&#xD;
          6. The following applies to male subjects:&#xD;
&#xD;
               1. Agrees to use a condom or abstinence, and agrees to refrain from sperm donation&#xD;
                  from date of informed consent signing through the 30 days after completing the&#xD;
                  double-blind study drug or&#xD;
&#xD;
               2. Has documentation of azoospermia or vasectomy&#xD;
&#xD;
          7. Non-smoker (or other nicotine user) as determined by history (no nicotine use over the&#xD;
             past 6 months) and a negative cotinine test at screening and Day -1&#xD;
&#xD;
          8. Body mass index between 18 and 32 kg/m2 inclusive at screening, and weighs at least 50&#xD;
             kg at screening&#xD;
&#xD;
          9. No clinically significant vital sign findings including no clinically significant&#xD;
             abnormal findings related to their systolic or diastolic BP at screening or prior to&#xD;
             dosing on Day 1, per the investigator's judgment.&#xD;
&#xD;
         10. No clinically significant abnormal findings in 12-lead ECG, per the investigator's&#xD;
             judgment, at screening or prior to dosing on Day 1&#xD;
&#xD;
         11. No clinically significant abnormalities in hematology, clinical chemistry, and&#xD;
             urinalysis results that would interfere with the study assessments at screening&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. History of any illness or condition that in the opinion of the investigator could&#xD;
             confound the results of the study or pose additional risk when administered IMP, such&#xD;
             as clinically significant history or evidence of cardiovascular, respiratory, hepatic,&#xD;
             renal, gastrointestinal, endocrine, neurological, immunological, or psychiatric&#xD;
             disorder(s) as determined by the investigator or designee&#xD;
&#xD;
          2. Concurrent disease or condition, that, in the opinion of the investigator, would make&#xD;
             the subject unsuitable for participation in the clinical study&#xD;
&#xD;
          3. Any of the following findings on a 12-lead ECG done at screening:&#xD;
&#xD;
               1. HR &lt; 45 bpm or &gt; 95 bpm&#xD;
&#xD;
               2. QTcF &gt; 450 msec for males and &gt;470 msec for females&#xD;
&#xD;
               3. PR &gt; 220 msec&#xD;
&#xD;
               4. QRS duration &gt; 110 msec&#xD;
&#xD;
               5. ST segment abnormal&#xD;
&#xD;
               6. T-wave changes&#xD;
&#xD;
               7. QRS, ST, or T-wave findings making it technically difficult to determine the QT&#xD;
                  intervals&#xD;
&#xD;
          4. Any of the following on 24-hour ambulatory ECG (Holter) monitoring at screening:&#xD;
&#xD;
             a. Supraventricular ectopy i. Singlets: &gt; 200 / 24 hours ii. Couplets: &gt; 20 / hour&#xD;
             iii. Runs: &gt; 10 beats b. Ventricular ectopy i. Unifocal singlets: &gt; 100 / 24 hours ii.&#xD;
             Unifocal couplets: &gt; 20 / hour iii. Complex of multifocal singlets: &gt; 50 / 24 hours&#xD;
             iv. Complex of multifocal couplets: &gt; 10 / 24 hours v. Any Run (ventricular&#xD;
             tachycardia) c. Heart rate i. &lt; 40 bpm for 1 minute while awake ii. &lt; 35 bpm for 3&#xD;
             minutes while asleep iii. &gt; 120 bpm for 3 minutes (when not exercising) iv. Pauses &gt;&#xD;
             2000 msec d. 2nd or 3rd degree AV block e. Intraventricular conduction delay (IVCD)&#xD;
             with QRS duration &gt; 120 msec or right bundle branch block (RBBB) or left buddle branch&#xD;
             block (LBBB) other than rare RBBB f. Atrial flutter or atrial fibrillation regardless&#xD;
             of rate&#xD;
&#xD;
          5. Disorder that would interfere with the absorption, distribution, metabolism, or&#xD;
             excretion of drugs as determined by the investigator&#xD;
&#xD;
          6. History of alcohol abuse or drug abuse (including cannabis, cocaine, and opioids) in&#xD;
             the year prior to screening&#xD;
&#xD;
          7. Positive alcohol test at screening or Day -1.&#xD;
&#xD;
          8. Positive drug test (including but not limited to cocaine, amphetamines, barbiturates,&#xD;
             opiates, benzodiazepines) at screening or Day -1.&#xD;
&#xD;
             a. A positive drug test for cannabinoids at screening will be allowed if the subject&#xD;
             agrees to abstain from use of all forms of cannabinoids during screening and&#xD;
             throughout the study and has a negative test at Day -1&#xD;
&#xD;
          9. Positive screening test for Hepatitis B surface antigen, Hepatitis C antibody, or&#xD;
             human immunodeficiency virus (HIV) antibody.&#xD;
&#xD;
         10. Unwilling to limit consumption of coffee and caffeine-containing foods and beverages&#xD;
             from Day -1 until discharge on Day 8.&#xD;
&#xD;
         11. Unwilling to avoid use of alcohol or alcohol-containing foods, medications, or&#xD;
             beverages from Day -1 until discharge on Day 8.&#xD;
&#xD;
         12. Subject has donated blood (&gt; 500 mL) or blood products within 56 days prior to Day -1.&#xD;
&#xD;
         13. Use of vitamins from Day -7 until end-of-study follow up call, and use of&#xD;
             over-thecounter (OTC) medications, prescription medications, or herbal remedies from&#xD;
             Day - 14 until end-of-study follow-up call. By exception, acetaminophen â‰¤ 1000 mg/day&#xD;
             is permitted except within 48 hours prior to Day -1. Hormone replacement therapy (HRT)&#xD;
             and hormonal contraception is allowed throughout the study. The Medical Monitor and&#xD;
             Principal Investigator may allow certain OTC medications by exception if they are not&#xD;
             likely to affect study conduct and output.&#xD;
&#xD;
         14. Use of an investigational drug within 30 days prior to Day 1 dosing.&#xD;
&#xD;
         15. Unwilling to abstain from vigorous exercise from Day -1 until discharge on Day 8.&#xD;
&#xD;
         16. Problems understanding the protocol requirements, instructions and study related&#xD;
             restrictions, the nature, scope, and possible consequences of the clinical study.&#xD;
&#xD;
         17. Unlikely to comply with the protocol requirements, instructions, and study related&#xD;
             restrictions; e.g., uncooperative attitude, unavailable for follow-up call, and/or&#xD;
             improbability of completing the clinical study.&#xD;
&#xD;
         18. History of bleeding disorders (i.e., severe hemorrhage, melena, rectal bleeding,&#xD;
             nosebleeds, bruising, etc.).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Robert Williams, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Davita Clinical Research</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>DaVita Clinical Research</name>
      <address>
        <city>Lakewood</city>
        <state>Colorado</state>
        <zip>80228</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2017</verification_date>
  <study_first_submitted>October 10, 2016</study_first_submitted>
  <study_first_submitted_qc>October 12, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 14, 2016</study_first_posted>
  <last_update_submitted>January 27, 2017</last_update_submitted>
  <last_update_submitted_qc>January 27, 2017</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 31, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>N91115</keyword>
  <keyword>Cavosonstat</keyword>
  <keyword>Healthy Volunteer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cystic Fibrosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

